Literature DB >> 9088851

What's the RAGE? The receptor for advanced glycation end products (RAGE) and the dark side of glucose.

S D Yan1, D Stern, A M Schmidt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9088851     DOI： 10.1046/j.1365-2362.1996.00072.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN： 0014-2972            Impact factor:   4.686


× No keyword cloud information.
  10 in total

Review 1.  Human cerebral neuropathology of Type 2 diabetes mellitus.

Authors:  Peter T Nelson; Charles D Smith; Erin A Abner; Frederick A Schmitt; Stephen W Scheff; Gregory J Davis; Jeffrey N Keller; Gregory A Jicha; Daron Davis; Wang Wang-Xia; Adria Hartman; Douglas G Katz; William R Markesbery
Journal:  Biochim Biophys Acta       Date:  2008-08-22

2.  High-mobility group box-1 protein promotes angiogenesis after peripheral ischemia in diabetic mice through a VEGF-dependent mechanism.

Authors:  Federico Biscetti; Giuseppe Straface; Raimondo De Cristofaro; Stefano Lancellotti; Paola Rizzo; Vincenzo Arena; Egidio Stigliano; Giovanni Pecorini; Kensuke Egashira; Giulia De Angelis; Giovanni Ghirlanda; Andrea Flex
Journal:  Diabetes       Date:  2010-03-03       Impact factor: 9.461

Review 3.  Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications.

Authors:  A Bierhaus; P P Nawroth
Journal:  Diabetologia       Date:  2009-07-28       Impact factor: 10.122

4.  Harnessing neurogenesis in the adult brain-A role in type 2 diabetes mellitus and Alzheimer's disease.

Authors:  Orly Lazarov; Richard D Minshall; Marcelo G Bonini
Journal:  Int Rev Neurobiol       Date:  2020       Impact factor: 3.230

Review 5.  Cognitive dysfunction and diabetes mellitus.

Authors:  Christopher T Kodl; Elizabeth R Seaquist
Journal:  Endocr Rev       Date:  2008-04-24       Impact factor: 19.871

6.  Inhibitors of Advanced Glycation End Product (AGE) Formation and Accumulation.

Authors:  Karly C Sourris; Anna Watson; Karin Jandeleit-Dahm
Journal:  Handb Exp Pharmacol       Date:  2021

Review 7.  Ectodomain shedding of the receptor for advanced glycation end products: a novel therapeutic target for Alzheimer's disease.

Authors:  Ling Zhang; Rolf Postina; Yingqun Wang
Journal:  Cell Mol Life Sci       Date:  2009-12       Impact factor: 9.261

Review 8.  Insulin resistance: an additional risk factor in the pathogenesis of cardiovascular disease in type 2 diabetes.

Authors:  Tushar P Patel; Komal Rawal; Ashim K Bagchi; Gauri Akolkar; Nathalia Bernardes; Danielle da Silva Dias; Sarita Gupta; Pawan K Singal
Journal:  Heart Fail Rev       Date:  2016-01       Impact factor: 4.214

9.  PPARγ agonists regulate bidirectional transport of amyloid-β across the blood-brain barrier and hippocampus plasticity in db/db mice.

Authors:  Hao Wang; Fang Chen; Kai Long Zhong; Su Su Tang; Mei Hu; Yan Long; Ming Xing Miao; Jian Min Liao; Hong Bing Sun; Hao Hong
Journal:  Br J Pharmacol       Date:  2015-12-19       Impact factor: 8.739

10.  Acute exposure to a precursor of advanced glycation end products induces a dual effect on the rat pancreatic islet function.

Authors:  Ghada Elmhiri; Luiz Felipe Barella; Didier Vieau; Sylvaine Camous; Paulo C F Mathias; Latifa Abdennebi-Najar
Journal:  Int J Endocrinol       Date:  2014-11-17       Impact factor: 3.257
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.